Review
Cell Biology
Alejandro Egea-Zorrilla, Laura Vera, Borja Saez, Ana Pardo-Saganta
Summary: The lung epithelium exhibits remarkable regenerative capacity in response to injury, but this repair mechanism is often compromised in chronic lung diseases. Recent studies have identified epithelial cells with progenitor behavior that play a crucial role in tissue repair and have explored mechanisms of lung regeneration in mice and humans. Therapeutic strategies and cell-based approaches have been investigated for promoting lung regeneration in conditions such as idiopathic pulmonary fibrosis, with challenges and limitations still needing to be addressed in applying these therapies for patient benefit.
Article
Medicine, General & Internal
Dieter Munker, Paola Arnold, Gabriela Leuschner, Michael Irlbeck, Sebastian Michel, Teresa Kauke, Bruno Meiser, Juergen Behr, Nikolaus Kneidinger, Tobias Veit
Summary: This retrospective study evaluated the potential effects of immunosuppressants and antifibrotics on the perioperative course of patients with interstitial lung diseases undergoing lung transplantation. The results showed that pretreatment with antifibrotics could shorten the duration of mechanical ventilation and reduce the occurrence of de novo donor-specific antibodies. Therefore, the use of antifibrotics alone or in combination with immunosuppressive therapy in lung transplant patients with fibrotic lung diseases is safe and may have beneficial effects.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Immunology
Arno Vanstapel, Roel Goldschmeding, Roel Broekhuizen, Tri Nguyen, Annelore Sacreas, Janne Kaes, Tobias Heigl, Stijn E. Verleden, Alexandra De Zutter, Geert Verleden, Birgit Weynand, Erik Verbeken, Laurens J. Ceulemans, Dirk E. Van Raemdonck, Arne P. Neyrinck, Helene M. Schoemans, Bart M. Vanaudenaerde, Robin Vos
Summary: CTGF expression is increased in end-stage CLAD and pulmonary GVHD. Higher CTGF levels are found in BAL of RAS patients at CLAD diagnosis. These results suggest a potential role for CTGF in CLAD, especially in RAS and pulmonary GVHD.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Respiratory System
Eleanor Valenzi, Haopu Yang, John C. Sembrat, Libing Yang, Spencer Winters, Rachel Nettles, Daniel J. Kass, Shulin Qin, Xiaohong Wang, Michael M. Myerburg, Barbara Methe, Adam Fitch, Jonathan K. Alder, Panayiotis Benos, Bryan J. McVerry, Mauricio Rojas, Alison Morris, Georgios D. Kitsios
Summary: The study revealed the heterogeneity of lung microbiota in patients with IPF, with different bacterial loads and compositions associated with distinct clinical outcomes.
Article
Medicine, General & Internal
Zhijun Zhou, Barish H. Edil, Min Li
Summary: Gastrointestinal cancers, especially pancreatic cancer, pose a significant challenge to public health. Neoadjuvant chemotherapy offers some patients the chance for radical resection. An optimal chemotherapy regimen should maximize anti-tumor efficacy while maintaining manageable safety. Surgical advancements further enhance outcomes for these patients.
Article
Medicine, General & Internal
Liming Cao, Yilan Sun, Fei Chen
Summary: COVID-19 can lead to immunosuppression and disruption of tight junctions, increasing the risk of opportunistic infections. In this case, a immunocompromised patient developed pulmonary nocardiosis. This case highlights the importance of careful diagnosis and treatment.
FRONTIERS IN MEDICINE
(2023)
Article
Oncology
Guilin Peng, Chao Yang, Mengyang Liu, Weixue Cui, Bastian Grande, Christina Kao, Piergiorgio Solli, George Makdisi, Xin Xu, Jianxing He
Summary: This study reports a case of an ILD patient who received a left lung transplantation early on, with subsequent tumor progression in the native right lung. The patient underwent a secondary lung transplant and has experienced no postoperative recurrence so far. Effective surveillance methods are crucial for early detection of lung cancer in high-risk lung transplant patients.
TRANSLATIONAL LUNG CANCER RESEARCH
(2021)
Article
Multidisciplinary Sciences
Christopher S. King, Emily White, Shambhu Aryal, Oksana A. Shlobin, Anju Singhal, Whitney Brown, Christopher Thomas, Vikramjit Khangoora, Alan Nyquist, Kevin R. Flaherty, Steven D. Nathan, Joshua J. Mooney
Summary: This study aimed to determine the proportion of lung transplant listing in patients with idiopathic pulmonary fibrosis (IPF) and the characteristics associated with transplantation. The study found that only a small proportion of IPF patients were listed for lung transplant, and advanced age was the primary factor associated with failure to be listed. Further research is needed to determine the exact reasons for low rates of listing.
Review
Gastroenterology & Hepatology
Vlad Ratziu, Sven Francque, Arun Sanyal
Summary: Nonalcoholic steatohepatitis (NASH) has become a leading cause of chronic liver disease, and the need for effective treatments is urgent. Recent breakthroughs and progress in understanding the pathogenesis have set the stage for future therapeutic successes in NASH.
JOURNAL OF HEPATOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Han Yang, Yufang Liu, Longqing Chen, Juanjuan Zhao, Mengmeng Guo, Xu Zhao, Zhenke Wen, Zhixu He, Chao Chen, Lin Xu
Summary: Lung cancer is a prevalent and deadly disease, with limited treatment options, especially for advanced stage patients. However, recent advances in miRNA-based therapies show potential in improving prognosis and overcoming drug resistance. Clinical trials have demonstrated promising outcomes for siRNA and miRNA-based therapies. This review discusses the current state of miRNA-based therapies in lung cancer treatment and their challenges, offering new ideas for the development of novel lung cancer therapies.
Review
Pharmacology & Pharmacy
Hehua Guo, Jiazheng Sun, Siyu Zhang, Yalan Nie, Sirui Zhou, Yulan Zeng
Summary: Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease with an unknown cause and poorly understood pathogenesis. The transformation of fibroblasts into myofibroblasts, triggered by injury to the alveolar epithelial cells, and the excessive accumulation of extracellular matrix (ECM) components, such as collagen, play crucial roles in IPF progression. Two novel anti-fibrotic medications, pirfenidone and nintedanib, have shown efficacy in slowing down lung function decline and reducing hospitalization risk in IPF patients. However, lung transplantation remains the only potential curative measure for IPF, and various innovative therapeutic strategies are currently being investigated.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Respiratory System
Aparna C. Swaminathan, Anne S. Hellkamp, Megan L. Neely, Shaun Bender, Luca Paoletti, Eric S. White, Scott M. Palmer, Timothy P. M. Whelan, Daniel F. Dilling
Summary: This study identifies the factors associated with lung transplant or death in patients with idiopathic pulmonary fibrosis (IPF). Age, income, and access to lung transplant centers are found to influence the likelihood of receiving a lung transplant or dying. Interventions are needed to address the socioeconomic disparities in lung transplantation.
ANNALS OF THE AMERICAN THORACIC SOCIETY
(2022)
Review
Pharmacology & Pharmacy
Madhushri Sinha, Diana Zabini, Divya Guntur, Chandran Nagaraj, Peter Enyedi, Horst Olschewski, Wolfgang M. Kuebler, Andrea Olschewski
Summary: Fine control over chloride homeostasis is crucial for maintaining proper lung function. This paper reviews the role of chloride channels and transporters in the lung, discusses their involvement in various lung diseases, and highlights their therapeutic potential.
PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Surgery
Stefanie J. Hannan, Carlo J. Iasella, Rachel M. Sutton, Iulia D. Popescu, Ritchie Koshy, Robin Burke, Xiaoping Chen, Yingze Zhang, Joseph M. Pilewski, Chadi A. Hage, Pablo G. Sanchez, Annie Im, Rafic Farah, Jonathan K. Alder, John F. Mcdyer
Summary: This study found that lung transplant recipients with idiopathic pulmonary fibrosis (IPF-LTRs) who have short telomere length (TL) and rare telomere gene variants are at increased risk for hematologic complications. The research suggests that stratification for telomere-mediated pulmonary fibrosis in lung transplant candidates is necessary.
AMERICAN JOURNAL OF TRANSPLANTATION
(2023)
Article
Respiratory System
Mwelwa Chizinga, Tiago N. Machuca, Abbas Shahmohammadi, Divya C. Patel, Ayoub Innabi, Bashar Alzghoul, Vanessa Scheuble, Mauricio Pipkin, Borna Mehrad, Andres Pelaez, Christine Lin, Diana Gomez-Manjarres
Summary: This study found that there was no significant difference in 1-year survival between patients undergoing lung transplantation during AE-ILD and those transplanted with stable disease. Patients with AE-ILD who underwent transplantation had higher survival rates compared to those who were medically treated.